Clinical trials: Glucagon
Obesity
Incretin Physiology and Beta-cell Function Before and After Weight-loss
To evaluate the impact of laparoscopic adjustable gastric banding (LAGB) on beta-cell function, insulin sensitivity, incretin function, postprandial secretion of incretin hormones (glucagon-like peptide-1 (GLP-1) and…
- Trial name
- NCT00625040
- Testing
- Oral glucose tolerance test (OGTT), isoglycemic iv. clamp, liquid meal test, gastric emptying rate
- Where
- Denmark
- Volunteers
- 10 people
- Sponsor
- Glostrup University Hospital, Copenhagen
Type 2 Diabetes
Sitagliptin and Glucagon Counterregulation
To evaluate the effect of DPP-4 inhibition on glucagon counter-regulatory mechanisms at moderate hypoglycemia in metformin-treated subjects with T2DM
- Trial name
- SITACLAMP (NCT02256189)
- Testing
- Sitagliptin
- Where
- Sweden
- Volunteers
- 28 people
- Sponsor
- Lund University
Smoking Cessation, Weight, Body
Daily Liraglutide for Nicotine Dependence
This clinical research trial examines the effects of the GLP-1 receptor agonist liraglutide on smoking behavior, food intake, and weight gain.
- Trial name
- DAL (NCT03712098)
- Testing
- Liraglutide, Smoking Cessation Counseling
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Rebecca Ashare
Bariatric Surgery (Gastric Bypass)
Can Postprandial Reactive Hypoglycaemia be Reduced in Patients After Roux-en-Y Gastric Bypass With a Low Carbohydrate Diet?
Roux-en-Y gastric bypass (RYGB) accelerates nutrient delivery to the small intestine causing higher peak blood glucose concentration early after meal intake.
- Trial name
- NCT02665715
- Testing
- Low carbohydrate meals, Standard carbohydrate meals
- Where
- Denmark
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Amirsalar Samkani
Post-transplant Diabetes Mellitus
GLP-1 Effects on Insulin and Glucagon in PTDM
Post-transplantation diabetes mellitus (PTDM) develops in 10-15 % of all renal transplant recipients within 10 weeks after transplantation, and has been associated with increased risk of cardiovascular disease and impaired…
- Trial name
- NCT02591849
- Testing
- Glucagon-like peptide-1 (GLP-1), Isotonic saline, Hyperglycemic clamp
- Where
- Norway
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Oslo University Hospital
Non-diabetec Obesity, Obesity (Disorder)
Weekly GLP-1 Receptor Agonists in Obese Individuals Without Diabetes
This randomized controlled trial evaluates the efficacy of three weekly GLP-1 receptor agonists (dulaglutide, semaglutide, and tirzepatide) in non-diabetic obese adults.
- Trial name
- NCT07834398
- Testing
- Dulaglutide, Semagludtide, Tirzepatide
- Where
- Saudi Arabia
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Zagazig University
Diabetes Mellitus Type 1
The iLet Introduction Study: A Feasibility Study of the iLet, a Fully Integrated Bihormonal Bionic Pancreas
This study will compare two different models of a wearable bionic pancreas device (the iPhone-based bionic pancreas vs. the iLet bionic pancreas) in adult participant with type 1 diabetes.
- Trial name
- NCT02701257
- Testing
- iPhone bionic pancreas, iLet bionic pancreas, Xeris Xerisol glucagon
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Reactive Hypoglycemia
Treatment With Sitagliptin for Reactive Hypoglycemia Secondary to Dysinsulinism
The purpose of this study is to determine whether sitagliptin is effective in the treatment of reactive hypoglycemia by dysinsulinism.
- Trial name
- NCT00847080
- Testing
- Sitagliptin phosphate
- Where
- Mexico
- Volunteers
- 20 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Type 1 Diabetes Mellitus
Glucagon Counterregulation in Type 1 Diabetes
The purpose of this study is to find out whether the combination of insulin and pramlintide is better than insulin alone at helping the pancreas release glucagon in response to a low blood sugar episode.
- Trial name
- NCT03547427
- Testing
- Basal insulin alone, Basal pramlintide and reduced basal insulin, CGM
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Virginia
GLP1-R-related Disease, Tumor
Glucagon-like Peptide-1 Receptor PET/CT in GLP-1R Related Disease
To evaluate the potential usefulness of 68Ga/18F-Exendin 4 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various GLP-1R-related disease patients.
- Conditions
- GLP1-R-related Disease, Tumor, Insulinoma, Positron Emission Tomography
- Trial name
- NCT06725693
- Testing
- 18F/68Ga-Exendin 4
- Where
- 3 sites in China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Tianjin Medical University
Insulin Sensitivity
Effect of Physiologic Hyperglucogonemia on Adipocyte Metabolism
Purpose/Objectives: To investigate the effect of hyperglucagonemia on insulin action, particularly on adipose tissue. Research Design/Plan: Normal glucose tolerant subjects will be studied.
- Trial name
- Glucagon (NCT04300049)
- Testing
- Glucagon Infusion, Saline
- Where
- 2 sites in United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Short Bowel Syndrome, SBS
A Clinical Study of FT1 in Patients With Short Bowel Syndrome
The goal of this clinical trial is to learn if FT1 is safe and works to treat short bowel syndrome (SBS) in adults. It will also learn about the PK/PD profile of FT1.
- Trial name
- NCT07704047
- Testing
- FT1
- Where
- China
- Volunteers
- 8 people
- Sponsor
- Chongqing Peg-Bio Biopharm Co., Ltd.
Gastric Emptying, Glucagon-Like Peptide-1 Receptor Agonists
Effect of Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) on Gastric Emptying
This study aims to assess the effect of using Glucagon-like peptide-1 receptor agonists (GLP-1) receptor agonists on gastric emptying on surgical patients and whether specific guidelines need to be established for these patients.
- Conditions
- Gastric Emptying, Glucagon-Like Peptide-1 Receptor Agonists, Intermittent Fasting, Intraoperative Complication Due to Anesthesia
- Trial name
- NCT07140289
- Testing
- Ultrasound of gastric contents
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Wael Saasouh, MD
Liver Disease
Intravenous-Morphine and Glucagon-Usage Enhanced MR Cholangiography
Morphine can induce constriction of sphincter of oddi and glucagon can facilitate bile secretion and dilatation of bile duct. We conduct this randomized double blinded study to evaluate the effect of enhancement in MRCP using…
- Trial name
- NCT00155376
- Testing
- morphine and glucagon
- Where
- Taiwan
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Incretin Action, Obesity
Oxyntomodulin, Mechanisms of Action in Relation to Appetite, Food Intake, Gastric Emptying and Energy Expenditure.
Tiny molecules (hormones) are released from the bowels and other organs to the bloodstream in response to meals in order to orchestrate the metabolism.
- Trial name
- NCT01232244
- Testing
- GLP-1 infusion, Glucagon infusion, Oxyntomodulin infusion
- Where
- Denmark
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Diabetic Kidney Disease
The Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Diabetic Kidney Disease
Diabetic kidney disease (DKD) is a devastating complication of diabetes, that in it's worst form, can lead to early cardiovascular death or kidney failure.
- Trial name
- NCT01847313
- Testing
- Liraglutide
- Where
- Ireland
- Volunteers
- 20 people
- Sponsor
- Karl Neff
Obesity & Overweight, Diabetes (DM)
Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists
This study examines how adults who take a GLP-1 receptor agonist medication (such as semaglutide [Ozempic, Wegovy, Rybelsus], liraglutide [Saxenda, Victoza], or tirzepatide [Mounjaro, Zepbound]) perform resistance (strength)…
- Trial name
- NCT07702461
- Testing
- Glucagon-Like Peptide-1 Agonist (GLP-1)
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Ohio State University
Healthy Adult Subject
A Relative Bioavailability and Food Effect Study of HDM1002 in Healthy Subjects
The main purpose of this study is to evaluate the effect of formulation on relative bioavailability of HDM1002, and the food effect on pharmacokinetics of HDM1002.
- Trial name
- NCT06608329
- Testing
- HDM1002
- Where
- China
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Gastric Cancer, Dumping Syndrome
Gastrectomy, Eating Behaviour and GLP-1
Patients who have undergone gastrectomy (removal of the stomach) to treat or prevent cancer are known to have a significantly reduced quality of life. To date, there is very little information on the physiological causes of this.
- Trial name
- NCT02971631
- Testing
- Exendin 9-39
- Where
- United Kingdom
- Volunteers
- 5 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Psoriatic Arthritis (PsA)
Impact of Glucagon-like Peptide-1 (GLP-1) Analogs on Disease Outcomes in Psoriatic Arthritis: A Pragmatic Randomized Controlled Trial
Psoriatic arthritis (PsA) is a chronic inflammatory condition that affects the joints but can also have an effect on multiple parts of the body.
- Trial name
- NCT07111494
- Testing
- GLP-1 agonists, Nutrition Counseling
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Medical College of Wisconsin